iCAD,
Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that the Company
will showcase its suite of Computer-Aided Detection (CAD) and advanced
imaging solutions at the Radiological Society of North America (RSNA) 99th
Annual Meeting being held December 1-6, 2013 in Chicago. iCAD will
feature the SecondLook® CAD technology for the identification
of breast cancer, including the PowerLook® Advanced
Mammography Platform® featuring iCAD partner Mātakina’s
VolparaDensity volumetric breast density assessment software. iCAD’s
VeraLook®, a revolutionary CAD solution for virtual
colonoscopy (CTC) designed to enhance clinician accuracy and
effectiveness by improving detection of colonic polyps, will also be on
display.
“The robust display of CAD and imaging solutions showcased in our booth
at this year’s RSNA are a testament to iCAD’s proven history and
long-time leadership position in the radiology space,” said Ken Ferry,
President and CEO of iCAD. “iCAD remains committed to the continued
development of advanced technologies, like CAD for 3D tomosynthesis, to
meet the needs of our more than 4,800 customers as well as delivering
cost-effective, innovative solutions that help radiologists detect
cancers with greater confidence.”
iCAD offers high-performance, upgradeable CAD systems and workflow
solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed
Tomography (CT). PowerLook AMP provides radiologists with the ability to
customize their CAD solution to meet the needs of their individual work
environment, including the integration of Mātakina’s VolparaDensity
assessment solution, an FDA-cleared technologic advancement providing
volumetric breast density measurements that correlate to the BI-RADS
breast density category to assist in interpreting digital mammograms.
The technology expands on iCAD’s SecondLook Digital algorithm and the
CAD metrics feature provides a rich set of clinical decision support
tools to aid in mammography screening. Shown to be effective in the
detection of colonic polyps, iCAD’s VeraLook CAD solution is designed to
integrate with specialized CTC reading environments to streamline the
reading process and improve clinician accuracy, productivity, and
workflow.
iCAD also recognizes the importance of 3D tomosynthesis to the diagnosis
of breast cancer. This technology provides radiologists with an
unprecedented amount of data to aid in their diagnosis. In order to
efficiently utilize this amount of information, radiologists need
additional tools to streamline their workflow. iCAD is working closely
with several of its OEM partners to design and develop a robust CAD
solution specifically for tomosynthesis that will optimize workflow for
the radiologists by making it easier to detect regions of interest. At
RSNA 2013, iCAD will display its latest version of this technology as a
“works in progress.”
In addition to a presence in the Invivo Corporation’s booth (#2700 in
South Building, Hall A), DynaCAD, iCAD’s MRI product suite for
quantification image analysis of the breast, prostate and other organs,
will also be featured in a Scientific Formal Presentation taking place
on Friday, December 6 from 10:30 a.m. to 12:00 p.m. in Room N230 in the
North Building. The session will discuss “Tumor Cellularity and the
Extravascular-Extracellular Space: Using Quantitative Imaging to
Evaluate Correlation Between ADC and DCE MRI in Human Gliomas,
Meningiomas and Cerebral Lymphomas,” a study co-authored by Naira
Muradyan, PhD, Lead Senior Research Scientist, iCAD, Inc., which may
provide new imaging biomarkers of brain tumor cellularity.
For additional information regarding iCAD and the technologies on
display at RSNA 2013, please visit http://www.icadmed.com/newsevents/rsna2013.htm.
About the Radiological Society of North America (RSNA)
RSNA
is an association of more than 53,000 radiologists, radiation
oncologists, medical physicists and related scientists, promoting
excellence in patient care and health care delivery through education,
research and technologic innovation. The Society is based in Oak Brook,
Ill. (RSNA.org)
About iCAD, Inc.
iCAD is an industry-leading provider of
Computer-Aided Detection (CAD) technologies, advanced image analysis,
workflow solutions and radiation therapies for the early identification
and treatment of common cancers. iCAD offers a comprehensive range of
high-performance, upgradeable CAD solutions for mammography and advanced
image analysis and workflow solutions for Magnetic Resonance Imaging,
for breast and prostate cancers and Computed Tomography for colorectal
cancer. iCAD’s Xoft System, offers radiation treatment for early-stage
breast cancer that can be administered in the form of Intraoperative
Radiation Therapy or accelerated partial breast irradiation. The Xoft
System is also cleared for the treatment of non-melanoma skin cancer and
gynecological cancers. For more information, call (877) iCADnow, or
visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this
News Release constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but
are not limited to, the Company’s ability to defend itself in litigation
matters, the Company’s ability to identify a replacement for the Axxent
FlexiShield Mini, the risks relating to the Company’s acquisition of
Xoft including, the expected benefits of the acquisition may not be
achieved in a timely manner, or at all; the Xoft business operations may
not be successfully integrated with iCAD’s and iCAD may be unable to
achieve the expected synergies, business and strategic objectives
following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological
obsolescence; increased competition; customer concentration; and other
risks detailed in the Company’s filings with the Securities and Exchange
Commission. The words “believe”, “demonstrate”, “intend”, “expect”,
“estimate”, “anticipate”, “likely”, and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue
reliance on those forward-looking statements, which speak only as of the
date the statement was made. The Company is under no obligation to
provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD,
please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section
of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
Copyright Business Wire 2013